Mari Carmen Vázquez-Borrego

Mari Carmen Vázquez-Borrego

Auto-generated profile, based on publicly available information

Mari Carmen Vázquez-Borrego

Department of Biochemistry and Molecular Biology University of Cordoba Cordoba Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Brain
Verified
Journal Article
Open access
PDF file
Antonio Carlos Fuentes-FayosAntonio Carlos Fuentes-Fayos
Antonio Carlos Fuentes-Fayos
MVMari C Vázquez-Borrego
Mari C Vázquez-Borrego
JJJuan Manuel Jiménez-Vacas
Juan Manuel Jiménez-Vacas
LBLeire Bejarano
Leire Bejarano
SPSergio Pedraza-Arevalo
Sergio Pedraza-Arevalo
Raul LuqueRaul Luque
Raul Luque
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12–16-month survival from diagnosis. Therefore, identification of new diagnostic, prognostic and therapeutic tools to tackle glioblastomas is urgently needed. Emerging evidence indicates that the cellular machinery controlling the splicing process (spliceosome) is altered in tumours, leading to oncogenic splicing events associated with tumour progression and aggressiveness. Here, we identify for the first time a profound dysregulation in the expression of relevant spliceosome components and splicing factors (at mRNA and protein levels) in well characterized cohorts of human high-grade astrocytomas, mostly glioblastomas, compared to healthy brain control samples, being SRSF3, RBM22, PTBP1 and RBM3 able to perfectly discriminate between tumours and control samples, and between proneural-like or mesenchymal-like tumours versus control samples from different mouse models with gliomas. Results were confirmed in four additional and independent human cohorts. Silencing of SRSF3, RBM22, PTBP1 and RBM3 decreased aggressiveness parameters in vitro (e.g. proliferation, migration, tumorsphere-formation, etc.) and induced apoptosis, especially SRSF3. Remarkably, SRSF3 was correlated with patient survival and relevant tumour markers, and its silencing in vivo drastically decreased tumour development and progression, likely through a molecular/cellular mechanism involving PDGFRB and associated oncogenic signalling pathways (PI3K-AKT/ERK), which may also involve the distinct alteration of alternative splicing events of specific transcription factors controlling PDGFRB (i.e. TP73). Altogether, our results demonstrate a drastic splicing machinery-associated molecular dysregulation in glioblastomas, which could potentially be considered as a source of novel diagnostic and prognostic biomarkers as well as therapeutic targets for glioblastomas. Remarkably, SRSF3 is directly associated with glioblastoma development, progression, aggressiveness and patient survival and represents a novel potential therapeutic target to tackle this devastating pathology.

1 November 2016 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
EREsther Rivero-Cortés
Esther Rivero-Cortés
MVMari C Vázquez-Borrego
Mari C Vázquez-Borrego
Manuel D. GaheteManuel D. Gahete
Manuel D. Gahete
LJLuis Jiménez-Reina
Luis Jiménez-Reina
Justo CastañoJusto Castaño
Justo Castaño
Somatostatin analogs (SSA) are the mainstay of pharmacological treatment for pituitary adenomas. However, some patients escape from therapy with octreotide, a somatostatin receptor 2 (sst2)-preferring SSA, and pasireotide, a novel multi-sst-preferring SSA, may help to overcome this problem. It has been proposed that correspondence between sst1-sst5 expression pattern and SSA-binding profile could predict patient’s response. To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in a series of 85 pituitary samples. Somatotropinomas expressed sst5>sst2, yet octreotide reduced [Ca2+]i more efficiently than pasireotide, while both SSA similarly decreased growth hormone release/expression and viability. Corticotropinomas predominantly expressed sst5, but displayed limited response to pasireotide, while octreotide reduced functional endpoints. Non-functioning adenomas preferentially expressed sst3 but, surprisingly, both SSA increased cell viability. Prolactinomas mainly expressed sst1 but were virtually unresponsive to SSA. Finally, both SSA decreased [Ca2+]i in normal pituitaries. In conclusion, both SSA act in vitro on pituitary adenomas exerting both similar and distinct effects; however, no evident correspondence was found with the sst1-sst5 profile. Thus, it seems plausible that additional factors, besides the simple abundance of a given sst, critically influence the SSA response.

21 December 2017 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
EVEva Venegas‐Moreno
Eva Venegas‐Moreno
MVMari C. Vazquez‐Borrego
Mari C. Vazquez‐Borrego
EDElena Dios
Elena Dios
NGNoelia Gros‐Herguido
Noelia Gros‐Herguido
AFAlvaro Flores-Martínez
Alvaro Flores-Martínez
ASAlfonso Soto-Moreno
Alfonso Soto-Moreno
Acromegaly is a hormonal disorder resulting from excessive growth hormone (GH) secretion frequently produced by pituitary adenomas and consequent increase in insulin‐like growth factor 1 (IGF‐I). Elevated GH and IGF‐I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and gastrointestinal morbidities. Somatostatin analogues (SSAs) form the basis of medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy in patients undergoing unsuccessful surgery. However, a considerable percentage of patients do not respond to SSAs treatment. Somatostatin receptors (SSTR1‐5) and dopamine receptors (DRD1‐5) subtypes play critical roles in the regulation of hormone secretion. These receptors are considered important pharmacological targets to inhibit hormone oversecretion. It has been proposed that decreased expression of SSTRs may be associated with poor response to SSAs. Here, we systematically examine SSTRs and DRDs expression in human somatotroph adenomas by quantitative PCR. We observed an association between the response to SSAs treatment and DRD4, DRD5, SSTR1 and SSTR2 expression. We also examined SSTR expression by immunohistochemistry and found that the immunohistochemical detection of SSTR2 in particular might be a good predictor of response to SSAs.

6 March 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
EVEva Venegas‐Moreno
Eva Venegas‐Moreno
AFAlvaro Flores-Martínez
Alvaro Flores-Martínez
EDElena Dios
Elena Dios
MVMari C. Vazquez‐Borrego
Mari C. Vazquez‐Borrego
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
ASAlfonso Soto-Moreno
Alfonso Soto-Moreno
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs) represent the primary medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery. However, a considerable proportion of patients do not adequately respond to SSAs treatment, and therefore, there is an urgent need to identify biomarkers predictors of response to SSAs. The aim of this study was to examine E‐cadherin expression by immunohistochemistry in fifty‐five GH‐producing pituitary tumours and determine the potential association with response to SSAs as well as other clinical and histopathological features. Acromegaly patients with tumours expressing low E‐cadherin levels exhibit a worse response to SSAs. E‐cadherin levels are associated with GH‐producing tumour histological subtypes. Our results indicate that the immunohistochemical detection of E‐cadherin might be useful in categorizing acromegaly patients based on the response to SSAs.

14 February 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MVMari Carmen Vázquez-Borrego
Mari Carmen Vázquez-Borrego
VGVandana Gupta
Vandana Gupta
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
Manuel D. GaheteManuel D. Gahete
Manuel D. Gahete
EVEva Venegas-Moreno
Eva Venegas-Moreno
Raul LuqueRaul Luque
Raul Luque
Purpose: Somatostatin-analogs (SSAs) are efficacious and safe treatments for a variety of neuroendocrine tumors, especially pituitary neuroendocrine tumors (PitNETs). Their therapeutic effects are mainly mediated by somatostatin receptors SST2 and SST5. Most SSAs, such as Octreotide/Lanreotide/Pasireotide, are either nonselective or activate mainly SST2. However, non-functioning pituitary tumors (NFPTs), the most common PitNET type, mainly express SST3 and finding peptides that activate this particular somatostatin-receptor has been very challenging. Therefore, the main objective of this study was to identify SST3-agonists and characterize their effects on experimental NFPT models. Experimental Design: Binding to SSTs and cAMP level determinations were used to screen a peptide library and identify SST3-agonists. Key functional parameters (cell-viability/caspase-activity/chromogranin-A secretion/mRNA expression/intracellular-signaling pathways) were assessed on NFPT primary cell cultures in response to SST3-agonists. Tumor growth was assessed in a preclinical PitNET mouse model treated with a SST3-agonist. Results: We successfully identified the first SST3-agonist peptides. SST3-agonists lowered cell-viability and chromogranin-A secretion, increased apoptosis in vitro, and reduced tumor growth in a preclinical PitNET model. As expected, inhibition of cell-viability in response to SST3-agonists defined two NFPTs populations: responsive and unresponsive, wherein responsive NFPTs expressed more SST3 than unresponsive NFPTs and exhibited a profound reduction of MAPK, PI3K-AKT/mTOR and JAK/STAT signaling pathways upon SST3-agonist treatments. Concurrently, SSTR3-silencing increased cell-viability in a subset of NFPTs. Conclusions: This study demonstrates that SST3-agonists activate signaling mechanisms that reduce NFPT cell-viability and inhibit pituitary tumor growth in experimental models that expresses SST3, suggesting that targeting this receptor could be an efficacious treatment for NFPTs.

26 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MVMari C. Vázquez-Borrego
Mari C. Vázquez-Borrego
Antonio Carlos Fuentes-FayosAntonio Carlos Fuentes-Fayos
Antonio Carlos Fuentes-Fayos
EVEva Venegas
Eva Venegas
EREsther Rivero-Cortés
Esther Rivero-Cortés
EDElena Dios
Elena Dios
Raul LuqueRaul Luque
Raul Luque
Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all brain tumors, and most have a sporadic origin. Recent studies suggest that altered alternative splicing and, consequently, appearance of aberrant splicing variants, is a common feature of most tumor pathologies. Moreover, spliceosome is considered an attractive therapeutic target in tumor pathologies, and the inhibition of SF3B1 (e.g., using pladienolide-B) has been shown to exert antitumor effects. Therefore, we aimed to analyze the expression levels of selected splicing-machinery components in 261 PitNETs (somatotropinomas/non-functioning PitNETS/corticotropinomas/prolactinomas) and evaluated the direct effects of pladienolide-B in cell proliferation/viability/hormone secretion in human PitNETs cell cultures and pituitary cell lines (AtT-20/GH3). Results revealed a severe dysregulation of splicing-machinery components in all the PitNET subtypes compared to normal pituitaries and a unique fingerprint of splicing-machinery components that accurately discriminate between normal and tumor tissue in each PitNET subtype. Moreover, expression of specific components was associated with key clinical parameters. Interestingly, certain components were commonly dysregulated throughout all PitNET subtypes. Finally, pladienolide-B reduced cell proliferation/viability/hormone secretion in PitNET cell cultures and cell lines. Altogether, our data demonstrate a drastic dysregulation of the splicing-machinery in PitNETs that might be associated to their tumorigenesis, paving the way to explore the use of specific splicing-machinery components as novel diagnostic/prognostic and therapeutic targets in PitNETs.